Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects

Clinical Pharmacokinetics

Volumn 52, Issue 9, 2013, Pages 783-792

  Haschke, Manuel ^a,b   Schuster, Manfred ^c   Poglitsch, Marko ^c   Loibner, Hans ^c   Salzberg, Marc ^d   Bruggisser, Marcel ^a,b   Penninger, Joseph ^e   Krähenbühl, Stephan ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c Apeiron Biologics Forschungs und Entwicklungsgesellschaft MbH   (Austria)

^d Medpace Switzerland ^*  (Switzerland)

^e INSTITUTE OF MOLECULAR BIOTECHNOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN[1-5]; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-8]; RECOMBINANT HUMAN ANGIOTENSIN CONVERTING ENZYME 2; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLEARANCE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; HEART RATE; HUMAN; IMMUNOGENICITY; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

ANGIOTENSIN I; ANGIOTENSIN II; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RECOMBINANT PROTEINS;

EID: 84883202259     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0072-7     Document Type: Article

References (36)

1. Dostal DE, Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res. 1999;85(7):643-50. (Pubitemid 29467853)
2. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, et al. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA. 1995;92(8):3521-5.
3. Krege JH, John SW, Langenbach LL, Hodgin JB, Hagaman JR, Bachman ES, et al. Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature. 1995;375(6527):146-8.
4. Hackenthal E, Paul M, Ganten D, Taugner R. Morphology, physiology, and molecular biology of renin secretion. Physiol Rev. 1990;70(4):1067-116. (Pubitemid 20364823)
5. Tanimoto K, Sugiyama F, Goto Y, Ishida J, Takimoto E, Yagami K, et al. Angiotensinogen-deficient mice with hypotension. J Biol Chem. 1994;269(50):31334-7. (Pubitemid 24379482)
6. Bernstein KE, Berk BC. The biology of angiotensin II receptors. Am J Kidney Dis. 1993;22(5):745-54. (Pubitemid 23330947)
7. Turner AJ, Hooper NM. The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci. 2002;23(4):177-83. (Pubitemid 34270600)
8. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension. 2001;38(3 Pt 2):635-8.
9. Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Mezzano S, Egido J. Renin-angiotensin system and renal damage: emerging data on angiotensin II as a proinflammatory mediator. Contrib Nephrol. 2001;135:123-37.
10. Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S, et al. Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension. 2001;38(6):1382-7. (Pubitemid 34033420)
11. Herr D, Rodewald M, Fraser HM, Hack G, Konrad R, Kreienberg R, et al. Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecol Oncol. 2008;109(3):418-25.
12. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417(6891):822-8. (Pubitemid 34670323)
13. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87(5):E1-9.
14. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275(43):33238-43.
15. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277(17):14838-43. (Pubitemid 34952556)
16. Chappell MC. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension. 2007;50(4):596-9. (Pubitemid 47442717)
17. Trask AJ, Averill DB, Ganten D, Chappell MC, Ferrario CM. Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats. Am J Physiol Heart Circ Physiol. 2007;292(6):H3019-24. (Pubitemid 47084554)
18. Lovren F, Pan Y, Quan A, Teoh H, Wang G, Shukla PC, et al. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol. 2008;295(4):H1377-84.
19. Chappell MC, Allred AJ, Ferrario CM. Pathways of angiotensin-(1-7) metabolism in the kidney. Nephrol Dial Transpl. 2001;16(Suppl 1):22-6. (Pubitemid 32492500)
20. Yamada K, Iyer SN, Chappell MC, Ganten D, Ferrario CM. Converting enzyme determines plasma clearance of angiotensin-(1-7). Hypertension. 1998;32(3):496-502. (Pubitemid 28429139)
21. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol. 2005;289(6):H2281-90. (Pubitemid 41698533)
22. de Lang A, Osterhaus AD, Haagmans BL. Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. Virology. 2006;353(2):474-81. (Pubitemid 44397144)
23. Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus AD, et al. The emerging role of ACE2 in physiology and disease. J Pathol. 2007;212(1):1-11. (Pubitemid 46746284)
24. Oudit GY, Kassiri Z, Patel MP, Chappell M, Butany J, Backx PH, et al. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res. 2007;75(1):29-39. (Pubitemid 46873522)
25. Zhong J, Guo D, Chen CB, Wang W, Schuster M, Loibner H, et al. Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension. 2011;57(2):314-22.
26. Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation. 2010;122(7):717-28, 18 p following 28.
27. Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes. 2010;59(2):529-38.
28. Osterreicher CH, Taura K, De Minicis S, Seki E, Penz-Osterreicher M, Kodama Y, et al. Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology. 2009;50(3):929-38.
29. Treml B, Neu N, Kleinsasser A, Gritsch C, Finsterwalder T, Geiger R, et al. Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. Crit Care Med. 2010;38(2):596-601.
30. Wysocki J, Ye M, Rodriguez E, Gonzalez-Pacheco FR, Barrios C, Evora K, et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension. 2010;55(1):90-8.
31. Mahmood I, Green MD. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet. 2005;44(4):331-47. (Pubitemid 40663681)
32. Iusuf D, Henning RH, van Gilst WH, Roks AJ. Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol. 2008;585(2-3):303-12.
33. Ahmad S, Simmons T, Varagic J, Moniwa N, Chappell MC, Ferrario CM. Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue. PloS one. 2011;6(12):e28501.
34. Park S, Bivona BJ, Kobori H, Seth DM, Chappell MC, Lazartigues E, et al. Major role for ACE-independent intrarenal ANG II formation in type II diabetes. Am J Physiol Ren Physiol. 2010;298(1):F37-48.
35. Baan J Jr, Chang PC, Vermeij P, Pfaffendorf M, van Zwieten PA. Effects of losartan on vasoconstrictor responses to angiotensin II in the forearm vascular bed of healthy volunteers. Cardiovasc Res. 1996;32(5):973-9. (Pubitemid 26342663)
36. Newby DE, Masumori S, Johnston NR, Boon NA, Webb DJ. Endogenous angiotensin II contributes to basal peripheral vascular tone in sodium deplete but not sodium replete man. Cardiovasc Res. 1997;36(2):268-75. (Pubitemid 27527351)